filmov
tv
Keynote & Closing: Gene Therapy for Primary Immunodeficiency Past, Present, Future

Показать описание
IDF's Rare of the Rare session, "Keynote & Closing of the Summit: Gene Therapy for Primary Immunodeficiency Past, Present, Future" was presented by Don Kohn, MD and IDF President & CEO, John G. Boyle on September 27, 2020.
Keynote & Closing: Gene Therapy for Primary Immunodeficiency Past, Present, Future
Chapter 1: ARVO 2014 Closing Keynote with Jean Bennett, MD, PhD
Chapter 2: ARVO 2014 Closing Keynote with Jean Bennett (Katherine High, MD)
Chapter 5: ARVO 2014 Closing Keynote with Jean Bennett (Arlene Drack, MD)
11 Philly Builds Bio+ Symposium 2022 - CLOSING KEYNOTE
Chapter 3: ARVO 2014 Closing Keynote with Jean Bennett (Jeannette Bennicelli, PhD)
Gene Therapy for Sensory Disorders
2023 MDA Conference: FDA Keynote Address On Genetic Therapy, Peter Marks MD PhD
Chapter 6: ARVO 2014 Closing Keynote with Jean Bennett (patient Yannick Duwe)
Cell & Gene Therapy Products 2020 Keynote: Simon Frost - Action Potential: A Parent’s Perspectiv...
Keynote address: Stem Cell & Gene Therapy Platforms
REW Keynote: Gene Therapy and Gene Editing for Orphan Diseases
Keynote: AAV-mediated gene therapy to the central nervous system: prospect for Angelman syndrome
Cell & Gene Therapy Products 2022 Keynote: Peter Marks, CBER, FDA
Cell & Gene Therapy Products 2023 Keynote Speaker: Becky Schweighardt, Grace Science LLC
Closing Keynote: Jill Vedder + Michael Hund + EB Research
CGT4HIVCURE2019: IN VIVO GENE THERAPY PANEL DISCUSSION & CLOSING REMARKS
ARVO 2022 Closing Keynote - Cynthia Toth & Joseph Izatt
ResearchCon 2022 | Something for Everyone
Announcing Opening & Closing Keynotes at #Summit4CI 2019
Chapter 4: ARVO 2014 Closing Keynote with Jean Bennett (Daniel Chung, OD)
Keynote Presentation: Extracellular Vesicle-Mediated mRNA-Based Gene Delivery..
Closing Keynote: Dented, Not Broken
Genetic therapies in neurodegeneration: cohorts, targets and approaches
Комментарии